Immune checkpoint inhibitors and chemotherapy in first-line NSCLC: a meta-analysis

被引：37

作者：

Petrelli, Fausto ^{[1
]}

Ferrara, Roberto ^{[2
]}

Signorelli, Diego ^{[2
]}

Ghidini, Antonio ^{[3
]}

Proto, Claudia ^{[2
]}

Roudi, Raheleh ^{[4
]}

Sabet, Mehrdad N. ^{[5
]}

Facelli, Sara ^{[6
]}

Garassino, Marina C. ^{[2
]}

Luciani, Andrea ^{[1
]}

Roviello, Giandomenico ^{[7
]}

机构：

[1] ASST Bergamo Ovest, Med Oncol Unit, I-24047 Treviglio, BG, Italy

[2] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, I-20133 Milan, Italy

[3] Casa Cura Igea, Med Oncol Unit, I-20126 Milan, Italy

[4] Univ Texas Hlth San Antonio, Dept Cell Syst & Anat, San Antonio, TX USA

[5] Minist Hlth & Med Educ, Canc Epidemiol Res & Treatment Ctr, Tehran, Iran

[6] Univ Florence, Sch Human Hlth Sci, Largo Brambilla 3, I-50134 Florence, Italy

[7] Univ Florence, Dept Hlth Sci, Sect Clin Pharmacol & Oncol, Florence, Italy

来源：

IMMUNOTHERAPY | 2021年 / 13卷 / 07期

关键词：

chemotherapy; combinations; first-line; immune checkpoint inhibitors; meta-analysis; non-small-cell lung cancer; PD-1; PD-L1; randomized trials; survival; CELL LUNG-CANCER; CARBOPLATIN; COMBINATION; PACLITAXEL; IPILIMUMAB; PEMBROLIZUMAB; ATEZOLIZUMAB; EFFICACY; ONCOLOGY; THERAPY;

D O I：

10.2217/imt-2020-0224

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Lay abstract We provide a meta-analysis of randomized controlled trials in first-line studies where immune checkpoint inhibitors were added to chemotherapy (CT) and were compared with CT alone. Nine articles were included for qualitative and quantitative synthesis. A meta-analysis of the nine randomized trials indicated a significant benefit in terms of overall survival (OS; hazard ratio: 0.75 [95% CI: 0.66-0.85]; p < 0.01). Only programmed death ligand-1 positive-high cancers were observed to receive a significant OS benefit. In this meta-analysis, there is moderate evidence that the addition of immune checkpoint inhibitors to CT may improve OS as compared with CT alone. This study is a meta-analysis of randomized controlled trials involving first-line studies in which immune checkpoint inhibitors were added to chemotherapy and were compared with chemotherapy alone. The primary end point was overall survival (OS). The analyses used random-effects models and the Grading of Recommendations Assessment, Development, and Evaluation system to rate the quality of the evidence. Nine articles were included for qualitative and quantitative synthesis. A meta-analysis of the nine randomized trials showed a significant benefit in terms of OS (hazard ratio: 0.75 [95% CI: 0.66-0.85]; p < 0.01). Only programmed death ligand-1 positive-high cancers derive a significant OS benefit. In this meta-analysis, there is moderate evidence that the addition of immune checkpoint inhibitors to chemotherapy may improve both OS compared with chemotherapy alone.

引用

页码：621 / 632

页数：12

共 35 条

[1] Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression [J].

Aguilar, E. J. ;

Ricciuti, B. ;

Gainor, J. F. ;

Kehl, K. L. ;

Kravets, S. ;

Dahlberg, S. ;

Nishino, M. ;

Sholl, L. M. ;

Adeni, A. ;

Subegdjo, S. ;

Khosrowjerdi, S. ;

Peterson, R. M. ;

Digumarthy, S. ;

Liu, C. ;

Sauter, J. ;

Rizvi, H. ;

Arbour, K. C. ;

Carter, B. W. ;

Heymach, J. V. ;

Altan, M. ;

Hellmann, M. D. ;

Awad, M. M. .

ANNALS OF ONCOLOGY, 2019, 30 (10) :1653-1659

[2]

Barlesi F., 2018, Ann. Oncol, V29, pVIII743, DOI DOI 10.1093/ANNONC/MDY424.066

[3] 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer [J].

Borghaei, Hossein ;

Langer, Corey J. ;

Gadgeel, Shirish ;

Papadimitrakopoulou, Vassiliki A. ;

Patnaik, Amita ;

Powell, Steven F. ;

Gentzler, Ryan D. ;

Martins, Renato G. ;

Stevenson, James P. ;

Jalal, Shadia I. ;

Panwalkar, Amit ;

Yang, James Chih-Hsin ;

Gubens, Matthew ;

Sequist, Lecia V. ;

Awad, Mark M. ;

Fiore, Joseph ;

Saraf, Sanatan ;

Keller, Steven M. ;

Gandhi, Leena .

JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (01) :124-129

[4] Oncology Meets Immunology: The Cancer-Immunity Cycle [J].

Chen, Daniel S. ;

Mellman, Ira .

IMMUNITY, 2013, 39 (01) :1-10

[5] Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis [J].

Conforti, Fabio ;

Pala, Laura ;

Bagnardi, Vincenzo ;

De Pas, Tommaso ;

Martinetti, Marco ;

Viale, Giuseppe ;

Gelber, Richard D. ;

Goldhirsch, Aron .

LANCET ONCOLOGY, 2018, 19 (06) :737-746

[6] Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis [J].

Dafni, Urania ;

Tsourti, Zoi ;

Vervita, Katerina ;

Peters, Solange .

LUNG CANCER, 2019, 134 :127-140

[7] Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers-Letter [J].

Ferrara, Roberto ;

Susini, Sandrine ;

Marabelle, Aurelien .

CLINICAL CANCER RESEARCH, 2019, 25 (11) :3468-3468

[8] Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer [J].

Gadgeel, Shirish ;

Rodriguez-Abreu, Delvys ;

Speranza, Giovanna ;

Esteban, Emilio ;

Felip, Enriqueta ;

Domine, Manuel ;

Hui, Rina ;

Hochmair, Maximilian J. ;

Clingan, Philip ;

Powell, Steven F. ;

Cheng, Susanna Yee-Shan ;

Bischoff, Helge G. ;

Peled, Nir ;

Grossi, Francesco ;

Jennens, Ross R. ;

Reck, Martin ;

Garon, Edward B. ;

Novello, Silvia ;

Rubio-Viqueira, Belen ;

Boyer, Michael ;

Kurata, Takayasu ;

Gray, Jhanelle E. ;

Yang, Jing ;

Bas, Tuba ;

Pietanza, M. Catherine ;

Garassino, Marina C. .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (14) :1505-+

[9] Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50% [J].

Gainor, J. F. ;

Rizvi, H. ;

Aguilar, E. Jimenez ;

Skoulidis, F. ;

Yeap, B. Y. ;

Naidoo, J. ;

Khosrowjerdi, S. ;

Mooradian, M. ;

Lydon, C. ;

Illei, P. ;

Zhang, J. ;

Peterson, R. ;

Ricciuti, B. ;

Nishino, M. ;

Roth, J. A. ;

Grishman, J. ;

Anderson, D. ;

Little, B. P. ;

Carter, B. W. ;

Arbour, K. ;

Sauter, J. L. ;

Mino-Kenudson, M. ;

Heymach, J., V ;

Digumarthy, S. ;

Shaw, A. T. ;

Awad, M. M. ;

Hellmann, M. D. .

ANNALS OF ONCOLOGY, 2020, 31 (03) :404-411

[10] Outcomes among patients (pts) with metastatic nonsquamous NSCLC with liver metastases or brain metastases treated with pembrolizumab (pembro) plus pemetrexed-platinum: Results from the KEYNOTE-189 study [J].

Garassino, Marina C. ;

Gadgeel, Shirish ;

Esteban, Emilio ;

Felip, Enriqueta ;

Speranza, Giovanna ;

De Angelis, Flavia ;

Domine, Manuel ;

Clingan, Philip ;

Hochmair, Maximilian J. ;

Powell, Steven F. ;

Cheng, Susanna Y. -S. ;

Bischoff, Helge G. ;

Peled, Nir ;

Grossi, Francesco ;

Jennens, Ross R. ;

Reck, Martin ;

Hui, Rina ;

Garon, Edward B. ;

Boyer, Michael ;

Rubio-Viqueira, Belen ;

Novello, Silvia ;

Kurata, Takayasu ;

Gray, Jhanelle E. ;

Cardellino, Anna ;

Yang, Jing ;

Pietanza, M. Catherine ;

Rodriguez-Abreu, Delvys .

CANCER RESEARCH, 2019, 79 (13)

← 1 2 3 4 →